Loading clinical trials...
Loading clinical trials...
A Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of Repeated Intravenous Doses of BTT-1023 in Patients With Plaque Psoriasis - a Double-blind Randomized Placebo-controlled Sequential Group Trial
Patients with plaque psoriasis will be enrolled. They will be dosed with repeated intravenous doses of BTT-1023 or placebo. During the trial, the safety of the treatments and the pharmacokinetics of BTT-1023 will be assessed. The patient allocation to treatment groups will occur at random, and the actual treatment will not be revealed to the investigator or to the patient during the trial.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
Biotie investigational site
Dresden, Dresden, Germany
Biotie investigational site
Leipzig, Leipzig, Germany
Biotie investigational site
Berlin, State of Berlin, Germany
Biotie investigational site
Berlin, State of Berlin, Germany
Biotie Investigational Site
Görlitz, Germany
Start Date
March 1, 2009
Primary Completion Date
August 1, 2010
Completion Date
August 1, 2010
Last Updated
November 16, 2010
26
ACTUAL participants
BTT1023
DRUG
Placebo
DRUG
BTT1023
DRUG
Lead Sponsor
Biotie Therapies Corp.
NCT07116967
NCT07250802
NCT07449702
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions